Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Free Cash Flow (2020 - 2025)

Summit Therapeutics (SMMT) has disclosed Free Cash Flow for 7 consecutive years, with -$102.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 109.64% year-over-year to -$102.1 million, compared with a TTM value of -$323.2 million through Dec 2025, down 127.23%, and an annual FY2025 reading of -$323.2 million, down 127.23% over the prior year.
  • Free Cash Flow was -$102.1 million for Q4 2025 at Summit Therapeutics, down from -$93.2 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $5.2 million in Q4 2022 and bottomed at -$102.1 million in Q4 2025.
  • Average Free Cash Flow over 5 years is -$32.9 million, with a median of -$22.1 million recorded in 2021.
  • The sharpest move saw Free Cash Flow surged 155.93% in 2022, then crashed 474.18% in 2023.
  • Year by year, Free Cash Flow stood at -$9.3 million in 2021, then soared by 155.93% to $5.2 million in 2022, then plummeted by 474.18% to -$19.5 million in 2023, then plummeted by 150.18% to -$48.7 million in 2024, then tumbled by 109.64% to -$102.1 million in 2025.
  • Business Quant data shows Free Cash Flow for SMMT at -$102.1 million in Q4 2025, -$93.2 million in Q3 2025, and -$66.4 million in Q2 2025.